ProMIS Neurosciences Receives FDA Fast Track Designation for PMN310 Alzheimer’s Treatment

ProMIS Neurosciences announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead Alzheimer’s disease (AD) therapeutic candidate, PMN310. The designation aims to accelerate the development and review of PMN310, which targets toxic misfolded proteins implicated in AD.

PMN310 is designed to selectively target the most harmful forms of amyloid-beta, potentially offering a safer and more effective treatment compared to existing therapies. Current Alzheimer’s treatments can cause serious side effects such as brain swelling and bleeding (ARIA), which PMN310 hopes to reduce.

Neil Warma, ProMIS CEO, emphasized the significance of the Fast Track status, highlighting the opportunity for increased regulatory engagement and a streamlined path toward approval. “This is a pivotal moment for ProMIS and the Alzheimer’s community,” Warma said.

PMN310 is currently being evaluated in the PRECISE-AD Phase 1b trial, focusing on safety, tolerability, pharmacokinetics, and biomarkers in early-stage Alzheimer’s patients. Interim six-month data are expected in the second quarter of 2026, with final results due by the end of that year.

Alzheimer’s affects over 6 million people in the U.S. and remains a leading cause of death and disability, underscoring the urgent need for improved therapeutic options. ProMIS aims to address this unmet medical need with PMN310, representing a potential next-generation treatment for the disease.